Evoke Pharma (EVOK)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	11.34 mm	11.34 mm	11.34 mm	11.34 mm	11.34 mm	11.34 mm
Cash burn (monthly)	(no burn)	(no burn)	428.55 k	491.53 k	272.90 k	443.73 k
Cash used (since last report)	n/a	n/a	2.27 mm	2.61 mm	1.45 mm	2.35 mm
Cash remaining	n/a	n/a	9.07 mm	8.73 mm	9.89 mm	8.99 mm
Runway (months of cash)	n/a	n/a	21.2	17.8	36.2	20.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

EVOK institutional ownership history Ownership history

72.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	7	17	-58.8%
Opened positions	3	4	-25.0%
Closed positions	13	3	+333.3%
Increased positions	0	2	EXIT
Reduced positions	3	1	+200.0%

13F shares	Current	Prev Q	Change
Total value	723.17 mm	1.67 bn	-56.6%
Total shares	1.08 mm	4.00 mm	-72.9%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Hirschman Orin	847.00 k	$631.00 k	0.0%
Nantahala Capital Management	84.69 k	$395.00 k	-87.5%
AIGH Capital Management	70.55 k	$338.76 mm	-91.7%
Bleichroeder	68.75 k	$327.25 mm	-91.7%
Corsair Capital Management	11.67 k	$55.54 mm	NEW
BlackRock	122.00	$581.00 k	NEW
C Citigroup	4.00	$20.00 k	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
AIGH Capital Management	70.55 k	-776.02 k	-91.7%
Bleichroeder	68.75 k	-756.25 k	-91.7%
Altium Capital Management	0.00	-692.44 k	EXIT
Nantahala Capital Management	84.69 k	-590.31 k	-87.5%
Geode Capital Management	0.00	-49.69 k	EXIT
Vanguard	0.00	-29.85 k	EXIT
Citadel Advisors	0.00	-11.91 k	EXIT
Corsair Capital Management	11.67 k	+11.67 k	NEW
STT State Street	0.00	-10.66 k	EXIT
Tower Research Capital	0.00	-7.48 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

EVOK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Feb 25	Matthew J D'Onofrio	Common Stock	Grant	Acquire A	No	No	3.65	6,849	25.00 k	8,820
20 Feb 25	Greg Pyszczymuka	Stock Option Common Stock	Grant	Acquire A	No	No	5.26	5,833	30.68 k	5,833
28 Jan 25	Matthew J D'Onofrio	Stock Option Common Stock	Grant	Acquire A	No	No	4.45	70,000	311.50 k	70,000
28 Jan 25	Widder Kenneth J	Stock Option Common Stock	Grant	Acquire A	No	No	4.45	5,833	25.96 k	5,833

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Evoke Pharma Highlights GIMOTI As A Leading Solution For Gastroparesis Treatment As Domperidone Supply Ends; FDA Posts Update As Mechanism To Obtain Unapproved Domperidone Expected To Lose Supply In Early 2025

19 Dec 24

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related

Press releases

From Benzinga Pro

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

6 Mar 25

SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti®

Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

24 Feb 25

SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on

Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

19 Dec 24

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and